Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study

E. R. Gaynor, J. M. Unger, Thomas P Miller, T. M. Grogan, Jr White L.A., G. M. Mills, S. P. Balcerzak, M. Varterasian, M. LeBlanc, R. I. Fisher

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen, alone (Southwest Oncology Group [SWOG] 9240) and with the chemosensitizers verapamil and quinine (SWOG 9125) to assess effects on response, survival and toxicity in intermediate- and high-grade advanced-stage non-Hodgkin's lymphoma (NHL). The results were compared with the historic group of patient's randomized to CHOP chemotherapy on Intergroup (INT) 0067 (SWOG 8516). Patients and Methods: All patients had biopsy-proven intermediate- or high-grade NHL (lymphoblastic histology excluded), were ambulatory and previously untreated, and had bulky stooge II, III, or IV disease. One hundred twelve patients were registered on SWOG 9240 and received cydophosphamide 750 mg/m2 by intravenous bolus day 1, doxorubicin 12.5 mg/m2/d and vincristine 0.5 mg/d delivered as a continuous 96-hour infusion on days 1 through 4, and dexamethasone 40 mg/d orally on days 1 through 4 (CYAD). Cycles were repeated every 21 days for eight cycles. One hundred patients on SWOG 9125 received the same chemotherapy and the chemosensitizers verapamil 240 mg bid and quinine 40 mg tid. Chemosensitizers were begun 24 hours before chemotherapy and continued for a total of 6 days. Results: Eighty-one patients were eligible for each study. The complete response (CR) rates were 39% on SWOG 9125 and 31% on SWOG 9240, With a median follow-up of 5.8 years on SWOG 9125 and 4.5 years on SWOG 9240, the 2-year failure-free survival (FFS) rate was 42% on SWOG 9125 and 41% on SWOG 9240. Two-year overall survival (OS) rate was 64% on SWOG 9125 and 58% on SWOG 9240. These results are comparable to a 44% CR rate, a 2-year FFS of 46%, and 2-year OS of 63% observed in 225 patients treated with CHOP on INT 0067 (SWOG 8516). Conclusion: CVAD combination chemotherapy alone or with the chemosentizers verapamil and quinine is not promising therapy with respect to improved response or OS in intermediate- and high-grade advanced-stage NHL.

Original languageEnglish (US)
Pages (from-to)750-755
Number of pages6
JournalJournal of Clinical Oncology
Volume19
Issue number3
StatePublished - Feb 1 2001
Externally publishedYes

Fingerprint

Lymphoma
Drug Therapy
Non-Hodgkin's Lymphoma
Quinine
Verapamil
Survival
Vincristine
Doxorubicin
Dexamethasone
Therapeutics
Survival Rate
Combination Drug Therapy
Cyclophosphamide
Histology
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma : A Southwest Oncology Group Study. / Gaynor, E. R.; Unger, J. M.; Miller, Thomas P; Grogan, T. M.; White L.A., Jr; Mills, G. M.; Balcerzak, S. P.; Varterasian, M.; LeBlanc, M.; Fisher, R. I.

In: Journal of Clinical Oncology, Vol. 19, No. 3, 01.02.2001, p. 750-755.

Research output: Contribution to journalArticle

Gaynor, ER, Unger, JM, Miller, TP, Grogan, TM, White L.A., J, Mills, GM, Balcerzak, SP, Varterasian, M, LeBlanc, M & Fisher, RI 2001, 'Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study', Journal of Clinical Oncology, vol. 19, no. 3, pp. 750-755.
Gaynor, E. R. ; Unger, J. M. ; Miller, Thomas P ; Grogan, T. M. ; White L.A., Jr ; Mills, G. M. ; Balcerzak, S. P. ; Varterasian, M. ; LeBlanc, M. ; Fisher, R. I. / Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma : A Southwest Oncology Group Study. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 3. pp. 750-755.
@article{fe0a4cc1679e4b569da170e2fc7cda14,
title = "Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study",
abstract = "Purpose: Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen, alone (Southwest Oncology Group [SWOG] 9240) and with the chemosensitizers verapamil and quinine (SWOG 9125) to assess effects on response, survival and toxicity in intermediate- and high-grade advanced-stage non-Hodgkin's lymphoma (NHL). The results were compared with the historic group of patient's randomized to CHOP chemotherapy on Intergroup (INT) 0067 (SWOG 8516). Patients and Methods: All patients had biopsy-proven intermediate- or high-grade NHL (lymphoblastic histology excluded), were ambulatory and previously untreated, and had bulky stooge II, III, or IV disease. One hundred twelve patients were registered on SWOG 9240 and received cydophosphamide 750 mg/m2 by intravenous bolus day 1, doxorubicin 12.5 mg/m2/d and vincristine 0.5 mg/d delivered as a continuous 96-hour infusion on days 1 through 4, and dexamethasone 40 mg/d orally on days 1 through 4 (CYAD). Cycles were repeated every 21 days for eight cycles. One hundred patients on SWOG 9125 received the same chemotherapy and the chemosensitizers verapamil 240 mg bid and quinine 40 mg tid. Chemosensitizers were begun 24 hours before chemotherapy and continued for a total of 6 days. Results: Eighty-one patients were eligible for each study. The complete response (CR) rates were 39{\%} on SWOG 9125 and 31{\%} on SWOG 9240, With a median follow-up of 5.8 years on SWOG 9125 and 4.5 years on SWOG 9240, the 2-year failure-free survival (FFS) rate was 42{\%} on SWOG 9125 and 41{\%} on SWOG 9240. Two-year overall survival (OS) rate was 64{\%} on SWOG 9125 and 58{\%} on SWOG 9240. These results are comparable to a 44{\%} CR rate, a 2-year FFS of 46{\%}, and 2-year OS of 63{\%} observed in 225 patients treated with CHOP on INT 0067 (SWOG 8516). Conclusion: CVAD combination chemotherapy alone or with the chemosentizers verapamil and quinine is not promising therapy with respect to improved response or OS in intermediate- and high-grade advanced-stage NHL.",
author = "Gaynor, {E. R.} and Unger, {J. M.} and Miller, {Thomas P} and Grogan, {T. M.} and {White L.A.}, Jr and Mills, {G. M.} and Balcerzak, {S. P.} and M. Varterasian and M. LeBlanc and Fisher, {R. I.}",
year = "2001",
month = "2",
day = "1",
language = "English (US)",
volume = "19",
pages = "750--755",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma

T2 - A Southwest Oncology Group Study

AU - Gaynor, E. R.

AU - Unger, J. M.

AU - Miller, Thomas P

AU - Grogan, T. M.

AU - White L.A., Jr

AU - Mills, G. M.

AU - Balcerzak, S. P.

AU - Varterasian, M.

AU - LeBlanc, M.

AU - Fisher, R. I.

PY - 2001/2/1

Y1 - 2001/2/1

N2 - Purpose: Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen, alone (Southwest Oncology Group [SWOG] 9240) and with the chemosensitizers verapamil and quinine (SWOG 9125) to assess effects on response, survival and toxicity in intermediate- and high-grade advanced-stage non-Hodgkin's lymphoma (NHL). The results were compared with the historic group of patient's randomized to CHOP chemotherapy on Intergroup (INT) 0067 (SWOG 8516). Patients and Methods: All patients had biopsy-proven intermediate- or high-grade NHL (lymphoblastic histology excluded), were ambulatory and previously untreated, and had bulky stooge II, III, or IV disease. One hundred twelve patients were registered on SWOG 9240 and received cydophosphamide 750 mg/m2 by intravenous bolus day 1, doxorubicin 12.5 mg/m2/d and vincristine 0.5 mg/d delivered as a continuous 96-hour infusion on days 1 through 4, and dexamethasone 40 mg/d orally on days 1 through 4 (CYAD). Cycles were repeated every 21 days for eight cycles. One hundred patients on SWOG 9125 received the same chemotherapy and the chemosensitizers verapamil 240 mg bid and quinine 40 mg tid. Chemosensitizers were begun 24 hours before chemotherapy and continued for a total of 6 days. Results: Eighty-one patients were eligible for each study. The complete response (CR) rates were 39% on SWOG 9125 and 31% on SWOG 9240, With a median follow-up of 5.8 years on SWOG 9125 and 4.5 years on SWOG 9240, the 2-year failure-free survival (FFS) rate was 42% on SWOG 9125 and 41% on SWOG 9240. Two-year overall survival (OS) rate was 64% on SWOG 9125 and 58% on SWOG 9240. These results are comparable to a 44% CR rate, a 2-year FFS of 46%, and 2-year OS of 63% observed in 225 patients treated with CHOP on INT 0067 (SWOG 8516). Conclusion: CVAD combination chemotherapy alone or with the chemosentizers verapamil and quinine is not promising therapy with respect to improved response or OS in intermediate- and high-grade advanced-stage NHL.

AB - Purpose: Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen, alone (Southwest Oncology Group [SWOG] 9240) and with the chemosensitizers verapamil and quinine (SWOG 9125) to assess effects on response, survival and toxicity in intermediate- and high-grade advanced-stage non-Hodgkin's lymphoma (NHL). The results were compared with the historic group of patient's randomized to CHOP chemotherapy on Intergroup (INT) 0067 (SWOG 8516). Patients and Methods: All patients had biopsy-proven intermediate- or high-grade NHL (lymphoblastic histology excluded), were ambulatory and previously untreated, and had bulky stooge II, III, or IV disease. One hundred twelve patients were registered on SWOG 9240 and received cydophosphamide 750 mg/m2 by intravenous bolus day 1, doxorubicin 12.5 mg/m2/d and vincristine 0.5 mg/d delivered as a continuous 96-hour infusion on days 1 through 4, and dexamethasone 40 mg/d orally on days 1 through 4 (CYAD). Cycles were repeated every 21 days for eight cycles. One hundred patients on SWOG 9125 received the same chemotherapy and the chemosensitizers verapamil 240 mg bid and quinine 40 mg tid. Chemosensitizers were begun 24 hours before chemotherapy and continued for a total of 6 days. Results: Eighty-one patients were eligible for each study. The complete response (CR) rates were 39% on SWOG 9125 and 31% on SWOG 9240, With a median follow-up of 5.8 years on SWOG 9125 and 4.5 years on SWOG 9240, the 2-year failure-free survival (FFS) rate was 42% on SWOG 9125 and 41% on SWOG 9240. Two-year overall survival (OS) rate was 64% on SWOG 9125 and 58% on SWOG 9240. These results are comparable to a 44% CR rate, a 2-year FFS of 46%, and 2-year OS of 63% observed in 225 patients treated with CHOP on INT 0067 (SWOG 8516). Conclusion: CVAD combination chemotherapy alone or with the chemosentizers verapamil and quinine is not promising therapy with respect to improved response or OS in intermediate- and high-grade advanced-stage NHL.

UR - http://www.scopus.com/inward/record.url?scp=0035253361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035253361&partnerID=8YFLogxK

M3 - Article

C2 - 11157027

AN - SCOPUS:0035253361

VL - 19

SP - 750

EP - 755

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -